Literature DB >> 30552390

A novel role for E2F3b in regulating cocaine action in the prefrontal cortex.

Hannah M Cates1, Rosemary C Bagot1,2, Elizabeth A Heller1,3, Immanuel Purushothaman1, Casey K Lardner1, Deena M Walker1, Catherine J Peña1, Rachael L Neve4, Li Shen1, Eric J Nestler5.   

Abstract

Drug abuse is a multifaceted disorder that involves maladaptive decision making. Long-lasting changes in the addicted brain are mediated by a complex circuit of brain reward regions. The prefrontal cortex (PFC) is one region in which chronic drug exposure changes expression and function of upstream transcriptional regulators to alter drug responses and aspects of the addicted phenotype. We reported recently that the transcription factor E2F3a is a critical mediator of cocaine responses in the nucleus accumbens. E2F3a is one of two splice variants of the E2f3 gene; the other is E2F3b. Another recent study predicted E2F3 as an upstream regulator of the transcriptional response to cocaine self-administration (SA) in PFC. Based on previous findings that E2F3a and E2F3b have divergent regulatory roles, we set out to study the putative transcriptional role of these transcripts in PFC in the context of repeated I.P. cocaine exposure. We implemented viral-mediated isoform-specific gene manipulation, RNA-sequencing, advanced bioinformatics analyses, and animal behavior to determine how E2F3a and E2F3b contribute to persistent cocaine-induced transcriptional changes in PFC. We show that E2F3b, but not E2F3a, in PFC is critical for cocaine locomotor and place preference behaviors. Interestingly, RNA-seq of PFC following E2f3b overexpression or I.P. cocaine exposure showed very different effects on expression levels of differentially expressed genes. However, we found that E2F3b drives a similar transcriptomic pattern to that of cocaine SA with overlapping upstream regulators and downstream pathways predicted. These findings reveal a novel transcriptional mechanism in PFC that controls behavioral and molecular responses to cocaine.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30552390      PMCID: PMC6372591          DOI: 10.1038/s41386-018-0296-1

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  35 in total

1.  Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins.

Authors:  G Leone; F Nuckolls; S Ishida; M Adams; R Sears; L Jakoi; A Miron; J R Nevins
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

Review 2.  Addiction, dopamine, and the molecular mechanisms of memory.

Authors:  J D Berke; S E Hyman
Journal:  Neuron       Date:  2000-03       Impact factor: 17.173

Review 3.  The neuropsychological basis of addictive behaviour.

Authors:  B J Everitt; A Dickinson; T W Robbins
Journal:  Brain Res Brain Res Rev       Date:  2001-10

Review 4.  Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission.

Authors:  P W Kalivas; N Volkow; J Seamans
Journal:  Neuron       Date:  2005-03-03       Impact factor: 17.173

Review 5.  Computational roles for dopamine in behavioural control.

Authors:  P Read Montague; Steven E Hyman; Jonathan D Cohen
Journal:  Nature       Date:  2004-10-14       Impact factor: 49.962

Review 6.  Use of herpes virus amplicon vectors to study brain disorders.

Authors:  Rachael L Neve; Kim A Neve; Eric J Nestler; William A Carlezon
Journal:  Biotechniques       Date:  2005-09       Impact factor: 1.993

Review 7.  Neural mechanisms of addiction: the role of reward-related learning and memory.

Authors:  Steven E Hyman; Robert C Malenka; Eric J Nestler
Journal:  Annu Rev Neurosci       Date:  2006       Impact factor: 12.449

8.  DeltaFosB induction in orbitofrontal cortex mediates tolerance to cocaine-induced cognitive dysfunction.

Authors:  Catharine A Winstanley; Quincey LaPlant; David E H Theobald; Thomas A Green; Ryan K Bachtell; Linda I Perrotti; Ralph J DiLeone; Scott J Russo; William J Garth; David W Self; Eric J Nestler
Journal:  J Neurosci       Date:  2007-09-26       Impact factor: 6.167

Review 9.  Neural systems of reinforcement for drug addiction: from actions to habits to compulsion.

Authors:  Barry J Everitt; Trevor W Robbins
Journal:  Nat Neurosci       Date:  2005-11       Impact factor: 24.884

10.  Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools.

Authors:  Paul D Thomas; Anish Kejariwal; Nan Guo; Huaiyu Mi; Michael J Campbell; Anushya Muruganujan; Betty Lazareva-Ulitsky
Journal:  Nucleic Acids Res       Date:  2006-07-01       Impact factor: 16.971

View more
  5 in total

1.  Transcriptomics in the nucleus accumbens shell reveal sex- and reinforcer-specific signatures associated with morphine and sucrose craving.

Authors:  Hannah L Mayberry; Charlotte C Bavley; Reza Karbalaei; Drew R Peterson; Angela R Bongiovanni; Alexandra S Ellis; Sara H Downey; Andre B Toussaint; Mathieu E Wimmer
Journal:  Neuropsychopharmacology       Date:  2022-02-21       Impact factor: 8.294

Review 2.  Key transcription factors mediating cocaine-induced plasticity in the nucleus accumbens.

Authors:  Collin D Teague; Eric J Nestler
Journal:  Mol Psychiatry       Date:  2021-06-02       Impact factor: 13.437

3.  Fosb Induction in Nucleus Accumbens by Cocaine Is Regulated by E2F3a.

Authors:  Hannah M Cates; Casey K Lardner; Rosemary C Bagot; Rachael L Neve; Eric J Nestler
Journal:  eNeuro       Date:  2019-04-01

4.  Alcohol Causes Lasting Differential Transcription in Drosophila Mushroom Body Neurons.

Authors:  Emily Petruccelli; Tariq Brown; Amanda Waterman; Nicolas Ledru; Karla R Kaun
Journal:  Genetics       Date:  2020-03-04       Impact factor: 4.562

5.  GeneCup: mining PubMed and GWAS catalog for gene-keyword relationships.

Authors:  Mustafa H Gunturkun; Efraim Flashner; Tengfei Wang; Megan K Mulligan; Robert W Williams; Pjotr Prins; Hao Chen
Journal:  G3 (Bethesda)       Date:  2022-05-06       Impact factor: 3.542

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.